Virtual drug screen reveals context-dependent inhibition of cardiomyocyte hypertrophy

Author:

Eggertsen Taylor G.ORCID,Saucerman Jeffrey J.ORCID

Abstract

ABSTRACTBackground and PurposePathological cardiomyocyte hypertrophy is a response to cardiac stress that typically leads to heart failure. Despite being a primary contributor to pathological cardiac remodeling, the therapeutic space that targets hypertrophy is limited. Here, we apply a network model to virtually screen for FDA-approved drugs that induce or suppress cardiomyocyte hypertrophy.Experimental ApproachA logic-based differential equation model of cardiomyocyte signaling was used to predict drugs that modulate hypertrophy. These predictions were validated against curated experiments from the prior literature. The actions of midostaurin were validated in new experiments using TGFβ- and NE-induced hypertrophy in neonatal rat cardiomyocytes.Key ResultsModel predictions were validated in 60 out of 70 independent experiments from the literature and identify 38 inhibitors of hypertrophy. We additionally predict that the efficacy of drugs that inhibit cardiomyocyte hypertrophy is often context dependent. We predicted that midostaurin inhibits cardiomyocyte hypertrophy induced by TGFβ, but not NE, exhibiting context dependence. We further validated this prediction by in vitro experimentation. Network analysis predicted critical roles for the PI3K and RAS pathways in the activity of celecoxib and midostaurin, respectively. We further investigated the polypharmacology and combinatorial pharmacology of drugs. Brigatinib and irbesartan in combination were predicted to synergistically inhibit cardiomyocyte hypertrophy.Conclusion and ImplicationsThis study provides a well-validated platform for investigating the efficacy of drugs on cardiomyocyte hypertrophy, and identifies midostaurin for consideration as an antihypertrophic drug.‘What is already known’- Cardiac hypertrophy is a leading predictor of heart failure.- Cardiomyocyte hypertrophy is driven by intracellular signaling pathways that are not targeted by current drugs‘What this study adds’- Computational model integrates 69 unique drugs to predict cardiomyocyte hypertrophy- Drug-induced inhibition of cardiomyocyte hypertrophy is context-dependent- Midostaurin inhibits TGFβ-induced cardiomyocyte hypertrophy‘Clinical significance’- Midostaurin is identified as a candidate antihypertrophic drug- Several FDA approved drugs are predicted to inhibit cardiomyocyte hypertrophy either individually or in combination.

Publisher

Cold Spring Harbor Laboratory

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3